Nutriband Inc. (NASDAQ:NTRB) Short Interest Update

Nutriband Inc. (NASDAQ:NTRB) was the recipient of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 222,300 shares, a decline of 20.9% from the February 28th total of 281,200 shares. Based on an average daily trading volume, of 201,300 shares, the short-interest ratio is currently 1.1 days. Currently, 4.4% of the company’s stock are short sold.

Institutional Trading of Nutriband

An institutional investor recently bought a new position in Nutriband stock. Haven Private LLC purchased a new position in shares of Nutriband Inc. (NASDAQ:NTRB) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 11,561 shares of the company’s stock, valued at approximately $54,000. Haven Private LLC owned approximately 0.10% of Nutriband at the end of the most recent reporting period. 19.70% of the stock is owned by hedge funds and other institutional investors.

Nutriband Stock Down 0.2 %

NTRB stock traded down $0.01 during midday trading on Wednesday, reaching $5.77. The company had a trading volume of 11,195 shares, compared to its average volume of 76,251. The company has a 50 day moving average of $7.07 and a two-hundred day moving average of $5.87. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.01. Nutriband has a 1 year low of $3.20 and a 1 year high of $11.78. The company has a market capitalization of $64.08 million, a P/E ratio of -8.13 and a beta of 1.12.

Wall Street Analysts Forecast Growth

Separately, Noble Financial assumed coverage on Nutriband in a report on Wednesday, January 22nd. They issued an “outperform” rating and a $13.00 target price on the stock.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.